Published in J Immunoassay Immunochem on January 01, 2013
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax (2010) 2.79
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med (2015) 2.44
Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest (2003) 2.04
New horizons in early stage COPD--improving knowledge, detection and treatment. Respir Med (2011) 1.56
Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer (2002) 1.53
Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol (2010) 1.47
Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol (2010) 1.41
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax (2010) 1.36
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score. Dtsch Arztebl Int (2017) 1.34
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31
Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol (2012) 1.28
Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax (2013) 1.20
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med (2014) 1.14
Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol (2009) 1.13
IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS One (2011) 1.13
MDCT assessment of airway wall thickness in COPD patients using a new method: correlations with pulmonary function tests. Eur Radiol (2008) 1.11
The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med (2009) 1.11
Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine (2010) 1.09
Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res (2003) 1.09
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother (2007) 1.08
Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res (2014) 1.08
Re: Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin 2014;30:913-22. Curr Med Res Opin (2014) 1.05
Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany. Int J Chron Obstruct Pulmon Dis (2012) 1.04
Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study. Respir Med (2011) 1.03
Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest (2003) 1.03
Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol (2007) 1.02
Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther (2005) 1.01
The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol (2008) 1.00
Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respir Med (2004) 0.99
Against all odds: anti-IgE for intrinsic asthma? Thorax (2013) 0.95
Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. Am J Respir Cell Mol Biol (2004) 0.93
TLR3 but not TLR7/8 ligand induces allergic sensitization to inhaled allergen. J Immunol (2012) 0.92
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res (2011) 0.91
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Adv Ther (2015) 0.91
Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir Res (2013) 0.89
Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol (2012) 0.89
Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med (2012) 0.88
c-kit expression in adenocarcinomas of the lung. Tumour Biol (2005) 0.87
Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array. Mediators Inflamm (2006) 0.87
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer (2007) 0.87
Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. Eur J Intern Med (2002) 0.86
Mast cells induce migration of dendritic cells in a murine model of acute allergic airway disease. Int Arch Allergy Immunol (2009) 0.86
Increased glutathione disulfide and nitrosothiols in sputum supernatant of patients with stable COPD. Chest (2004) 0.86
Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2003) 0.84
Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration (2002) 0.82
Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[(18)F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([(18)F]FEFE) for the in vivo visualisation and quantification of the beta2-adrenergic receptor status in lung. Bioorg Med Chem Lett (2003) 0.82
Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin (2006) 0.82
Evaluation of H2O2 and pH in exhaled breath condensate samples: methodical and physiological aspects. Biomarkers (2008) 0.82
Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma (2012) 0.81
Lung transplantation: a treatment option in end-stage lung disease. Dtsch Arztebl Int (2014) 0.81
SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods (2003) 0.81
Increased concentrations of glutathione in induced sputum of patients with mild or moderate allergic asthma. Ann Allergy Asthma Immunol (2004) 0.80
Chronic intestinal Mycobacteria infection: discrimination via VOC analysis in exhaled breath and headspace of feces using differential ion mobility spectrometry. J Breath Res (2011) 0.80
Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther (2013) 0.80
CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. J Allergy Clin Immunol (2011) 0.80
TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer (2008) 0.80
Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics (2005) 0.79
Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol (2011) 0.79
Regulatory T cells more effectively suppress Th1-induced airway inflammation compared with Th2. J Immunol (2011) 0.79
Measurement of exhaled nitric oxide: comparison of different analysers. Respirology (2010) 0.78
Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions. Respir Med (2005) 0.78
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma]. Med Klin (Munich) (2008) 0.78
Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J (2015) 0.77
Induced sputum methodology: Validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. J Lab Clin Med (2004) 0.77
Dissimilarity between seasonal changes in airway responsiveness to adenosine-5'-monophosphate and methacholine in patients with grass pollen allergic rhinitis: relation to induced sputum. Int Arch Allergy Immunol (2003) 0.77
Effect of histamine and adenosine 5'-monophosphate provocation on sputum neutrophils and related mediators in atopic patients. Ann Allergy Asthma Immunol (2005) 0.77
Dysfunctional inhibitory muscarinic receptors mediate enhanced histamine release in isolated human bronchi. Life Sci (2007) 0.77
Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung (2004) 0.77
Levels of soluble triggering receptor expressed on myeloid cells 1 in infectious exacerbations of chronic obstructive pulmonary disease. Respiration (2011) 0.76
Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med (2012) 0.76
[Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease]. Med Klin (Munich) (2009) 0.76
Allergen Responses Modified by a GATA3 DNAzyme. N Engl J Med (2015) 0.75
Sputum levels of reduced glutathione increase 24 hours after allergen challenge in isolated early, but not dual asthmatic responders. Int Arch Allergy Immunol (2004) 0.75
[Bronchodilators in chronic obstructive pulmonary disease (COPD)]. Med Klin (Munich) (2005) 0.75
Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen? Ther Adv Respir Dis (2011) 0.75
[Modern management of asthma]. MMW Fortschr Med (2009) 0.75
The recoveryELISA--a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med (2012) 0.75
Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. Respir Med (2011) 0.75
Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. Respir Med (2010) 0.75
[COPD, a systemic disease--nutritional approaches]. Med Klin (Munich) (2004) 0.75
[Guidelines for diagnosis and therapy of patients with asthma 2005. The most important aspects for adults]. Med Klin (Munich) (2006) 0.75
[Lung cancer]. Med Klin (Munich) (2008) 0.75
[National Disease Management Guideline for Asthma: recommendations and evidence for "asthma prevention" issues]. Z Arztl Fortbild Qualitatssich (2006) 0.75